@article{8f8a019246674c89acc2825463279f05,
title = "T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients",
abstract = "Background: Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune demyelinating disease. Its pathogenesis involves humoral and cellular immunity, with production of pro- and anti-inflammatory cytokines by T cells. Objective: To analyze the cytokine profile of cerebrospinal fluid (CSF) T cells in patients with relapsing-remitting MS (RRMS) and non-inflammatory controls. Methods: T cell cytokine production was analyzed by flow cytometry in CSF samples collected from 34 untreated RRMS patients and 20 age-matched controls. Immunofluorescence studies were performed in spinal cord MS active lesions. Results: Percentages of CSF-derived IL-17A, IL-17A/IL-22, and IL-17A/GM-CSF producing T cells were significantly higher in RRMS patients compared to controls. Percentages of T cells producing IFN-γ were lower in RRMS patients compared to controls. Patients in relapse showed higher percentages of CD4+ T cells producing IL-13 and GM-CSF compared to patients in remission. We found a positive correlation between percentages of IL-13+ T cells and the Expanded Disability Status Scale (EDSS; ρ = 0.5; p < 0.05). Meningeal IL-13-producing T cells were detected in spinal cord MS active lesions. Conclusion: We observed differences in IL-17, IL-22, and IFN-γ production by CSF T cells in RRMS versus controls and a positive correlation between IL-13-producing T cells and EDSS in RRMS patients.",
keywords = "Multiple sclerosis, T cells, cerebrospinal fluid, cytokines",
author = "Laura Ghezzi and Claudia Cantoni and Francesca Cignarella and Bryan Bollman and Cross, {Anne H.} and Amber Salter and Daniela Galimberti and Marina Cella and Laura Piccio",
note = "Funding Information: The authors thank Mr Michael Ramsbottom and Mr Bob Mikesell for technical assistance. We also thank the patients, study coordinators, and referring physicians who made this study possible. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a pilot grant from the National Multiple Sclerosis Society (NMSS; grant #PP2002). Partial funding for this study was provided by a Pilot Project Award from the Hope Center for Neurological Disorders at Washington University and by Fondazione Italiana Sclerosi Multipla (FISM; 2014/R/15). A.H.C. was supported in part by the Manny & Rosalyn Rosenthal–Dr. John L. Trotter MS Center Chair in Neuroimmunology of the Barnes-Jewish Hospital Foundation. During the course of this study, L.P. was supported by the Harry Weaver Neuroscience Scholar award of the National Multiple Sclerosis Society (NMSS; JF 2144A2/1); C.C. was supported by a FISM fellowship (2012/B/1) and subsequently by a NMSS fellowship (FG 2010-A1/2). Patients were seen for this study in the Neuroclinical Research Unit (NCRU) supported by grant C06RR014513. Publisher Copyright: {\textcopyright} The Author(s), 2019.",
year = "2020",
month = sep,
day = "1",
doi = "10.1177/1352458519852092",
language = "English",
volume = "26",
pages = "1172--1186",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
number = "10",
}